---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040810"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:52:32.994975+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma gets positive FDA feedback for Ropidoxuridine Phase 2; cash $6.8M

## Summary
- Positive FDA feedback in Type B PIND meeting for Ropidoxuridine; IND submission imminent to start Phase 2 trial for glioblastoma.
- Exclusive license from Georgetown University for predictive biomarker test for prostate cancer radiation therapy.
- Q3 2023 operating expenses (excl non-cash) $1.6M; cash, cash equivalents and marketable securities $6.8M at Sep 30, 2023.
- Expanded patent coverage on HDAC inhibitor platform; published manuscript on SP-2-225 immune response post-radiation.

## SEC filing metadata
- accession: 0001493152-23-040810
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315223040810/0001493152-23-040810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315223040810/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040810
- JSON: https://secwatch.observer/filing/0001493152-23-040810.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040810.txt

## Key facts
- Earnings Releases
  Shuttle Pharmaceuticals Holdings, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: issued a press release providing a corporate update in connection with the filing of our quarterly report on Form 10-Q for the period ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315223040810/0001493152-23-040810-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.